BIOMAT Database Logo BIOMAT Database Logo

Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy. 1995

N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Unité de Recherches de Physiopathologie Hépatique (INSERM), Hôpital Beaujon, Clichy, France.

The objective of this study was to look for HBV precore mutations in three patients with chronic active hepatitis B who developed HBV-DNA-positive/HBeAg-negative reactivation after HBe seroconversion induced by interferon therapy. Direct sequencing of polymerase chain reaction products was performed on serum collected before and after HBe seroconversion. In two patients precore sequence showed only wild-type HBV before and after interferon therapy. In one patient, precore sequence showed only wild-type HBV before interferon therapy and a mixed infection by wild-type HBV and precore mutant viruses (1858 and 1896 nucleotide mutations) after treatment. The presence of HBeAg/anti-HBe immune complexes was found after HBe seroconversion in all cases. Our results suggest that: 1) precore mutations are not always found in patients with chronic hepatitis B who develop HBV DNA-positive/HBeAg-negative reactivation; and 2) HBeAg negativity, despite the presence of wild-type HBV, might be due to HBeAg/anti-HBe immune complexes. We speculate that the production of these immune complexes may be favored by interferon therapy.

UI MeSH Term Description Entries
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006513 Hepatitis B e Antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G. HBeAg,Hepatitis B e Antigen,Hepatitis Be Antigen,e Antigen,e Antigens,HBe Ag-1,HBe Ag-2,Hepatitis Be Antigens,Antigen, Hepatitis Be,Antigen, e,Antigens, Hepatitis Be,Antigens, e,Be Antigen, Hepatitis,Be Antigens, Hepatitis
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon.
January 1995, Journal of viral hepatitis,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B.
January 2002, Journal of gastroenterology,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Hepatitis B virus precore/core variation and interferon therapy.
November 1995, Hepatology (Baltimore, Md.),
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Correlation Between Hepatitis B G1896A Precore Mutations and HBeAg in Chronic HBV Patients.
February 2015, Jundishapur journal of microbiology,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea.
January 2003, Journal of hepatology,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.
January 2011, Liver international : official journal of the International Association for the Study of the Liver,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon.
January 2003, Journal of hepatology,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
HBeAg-negative chronic hepatitis B.
January 2002, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Precore mutations and core clustering mutations in chronic hepatitis B virus infection.
January 1993, Gastroenterology,
N Talbodec, and M A Loriot, and M Gigou, and V Guigonis, and N Boyer, and A Bezeaud, and S Erlinger, and J P Benhamou, and P Marcellin
Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
February 2004, Liver international : official journal of the International Association for the Study of the Liver,
Copied contents to your clipboard!